^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Uveal Melanoma

Related cancers:
3d
Evolution of bispecific and multispecific antibodies in cancer therapy. (PubMed, Lancet Reg Health Eur)
It also outlines next generation directions, including higher order multispecific constructs, conditionally active antibodies, and payload conjugated multispecific formats. To consolidate these agents as an established therapeutic modality in oncology, priority should be given to rigorous understanding of mechanisms of action and toxicity, alongside rational optimisation of construct design and dosing, supported by robust prospective translational programmes.
Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
4d
Multidimensional immune ecological subtyping identifies RUNX1 as a prognostic factor in uveal melanoma. (PubMed, Discov Oncol)
Consistent with these subtype-specific features, CS1 tumors exhibited distinct sensitivities to dasatinib, lapatinib, paclitaxel, and cisplatin, indicating immune-state-associated therapeutic vulnerabilities. Together, these findings suggest a RUNX1-associated immunosuppressive tumor ecology in UVM and provide a conceptual framework for immune-state-guided therapeutic strategies.
Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1)
|
cisplatin • dasatinib • paclitaxel • lapatinib
5d
Trial initiation date
|
darovasertib (IDE196)
5d
Novel CRISPR-Cas9 BAP1 knockout pre-clinical tumor model recapitulates human melanoma tumorigenesis and immune evolution. (PubMed, Commun Biol)
Gene Set Enrichment Analysis confirms that lipid metabolic reprogramming, previously described in human tumors, is also a key feature of our model, validating its ability to recapitulate human disease biology. This study introduces a syngeneic preclinical model that mimics the immunosuppressive landscape of BAP1-deficient melanocytic tumors, enabling the development and optimization of new combination immunotherapies.
Preclinical • Journal
|
BAP1 (BRCA1 Associated Protein 1)
7d
Circulating Tumor DNA Monitoring in Patients with Uveal Melanoma Using Mutation-Agnostic Multiplex Drop-Off ddPCR Assays. (PubMed, Anal Chem)
Our mutation-agnostic multiplex drop-off ddPCR assays provide a sensitive, specific, and cost-effective alternative to targeted NGS and simplex ddPCR for ctDNA monitoring in UM. By minimizing reliance on prior knowledge of tumor genotype with NGS, these assays enable broader clinical applicability for real-time treatment monitoring in UM.
Journal • Circulating tumor DNA
|
GNAQ (G Protein Subunit Alpha Q) • SF3B1 (Splicing Factor 3b Subunit 1) • GNA11 (G Protein Subunit Alpha 11) • CYSLTR2 (Cysteinyl Leukotriene Receptor 2) • PLCB4 (Phospholipase C Beta 4)
|
SF3B1 mutation
7d
Clinicopathological Characteristics and BAP1 Expression in an Enucleation-Based Uveal Melanoma Cohort: A Single-Center Croatian Experience with Long-Term Follow-Up. (PubMed, Cancers (Basel))
The exceptionally high prevalence of BAP1 loss reflects the selection bias inherent in enucleation-based cohorts, which are enriched for large, molecularly high-risk tumors. This study provides the first comprehensive BAP1 immunohistochemical data from Croatia, contributing to the growing evidence that enucleation cohorts represent a distinct, biologically high-risk subgroup in which BAP1 immunohistochemistry offers limited discriminatory value. The extended follow-up of 11.2 years confirms the prolonged natural history of UM. Future multi-center studies incorporating molecular validation and diverse treatment modalities are needed to establish the prognostic utility of BAP1 across the full spectrum of UM disease.
Journal • BRCA Biomarker
|
BAP1 (BRCA1 Associated Protein 1)
10d
Long non-coding RNA MIAT Functions as a ceRNA to Protect Uveal Melanoma from Oxidative Stress by Sponging miR-4306 and Upregulating CXCR4. (PubMed, Exp Eye Res)
Our findings elucidated a critical lncRNA MIAT/miR-4306/CXCR4 regulatory axis that modulated oxidative stress resistance and apoptosis in UVM. This axis represented a promising therapeutic target, and the developed oxidative stress-related gene signature may serve as a valuable prognostic tool for UVM patients.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • MIAT (Myocardial Infarction Associated Transcript) • MIR4306 (MicroRNA 4306)
10d
First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study. (PubMed, J Immunother Cancer)
Single-cell immune repertoire profiling of serial peripheral blood sampling revealed substantial in vivo proliferation and expansion of a stem cell memory population in the endogenous T cell therapy product that achieved a >79% predominance of total circulating T cells by 3 weeks post-infusion in this non-lymphodepleted recipient. Although the patient's disease ultimately progressed, these findings demonstrate safety and proof of concept for an IL-7 treatment regimen for expansion of adoptively transferred T cells in vivo and induced memory differentiation in a heavily pretreated patient with refractory solid malignancy.
P1 data • Journal • First-in-human
|
CD8 (cluster of differentiation 8) • IL7 (Interleukin 7)
11d
Prevalence of the Predisposing Gene MBD4 for Uveal Melanoma. (PubMed, JAMA Ophthalmol)
These findings confirm that MBD4 is an important predisposing gene to uveal melanoma in the French population. This reinforces a strategy of broad patient screening given the therapeutic implications and the consequences of genetic counseling.
Journal
|
MBD4 (Methyl-CpG Binding Domain 4, DNA Glycosylase)
12d
The role of the tumor microenvironment and BAP1 protein expression in the prognosis of uveal melanoma (PubMed, Vestn Oftalmol)
Loss of BAP1 expression in combination with immune cell infiltration in the tumor microenvironment is associated with an increased risk of mortality in uveal melanoma. Combined assessment of BAP1 and immune markers enables more accurate patient stratification and refinement of prognostic evaluation.
Retrospective data • Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • BAP1 (BRCA1 Associated Protein 1) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
|
TMB-L
18d
Analysis of the mutational landscape of uveal melanoma and exploration of the mechanism of action of targeted drugs (ChiCTR2600119562)
P=N/A, N=20, The Second Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University
New trial
20d
Cell membrane-encased thylakoid as white light triggered PDT therapy for facile and targeted choroidal melanoma treatment. (PubMed, Bioact Mater)
Furthermore, the anti-tumor effect of CM-Thy was validated through various mechanisms involved in tumor formation such as angiogenesis and vasculogenic mimicry. Interestingly, the results from visible light experiments conducted in vitro also substantiated the remarkable therapeutic efficacy of this system for refractive eye disorders while providing innovative ideas for cross-species biological interventions.
Journal
|
NLRP3 (NLR Family Pyrin Domain Containing 3)